Brain Neoplasms Clinical Trial
Official title:
MRI for Early Identification of Underlying Pathology in Patients With Acute Intracerebral Hemorrhage
What happens in the borderzone of a cerebral hemorrhage remains widely onknown and furhter the best timing for doing MR to look for vascular pathology in cerebral hemorrhage has not yet been determined. In this study we do acute MRS, a non-invasive imaging mathod to detemine the biochemsty in the border zone and structural MRI for vascular malformation. We repeat structural MRI after 8 weeks.
In this study we want to investigate the ability of MRI to identify underlying pathology (tumor or vascular malformations) in acute patients admitted with intracerebral hemorrhage (ICH). Today MRI-scan is normally done 3-4 weeks after symptom onset but very little is known about the early use of MRI to detect underlying pathology. This would allow an early intervension and less uncertainty for the patients. We further want to investigate the metabolic penumbra-zone surrounding the hematoma. It is the current perception in the litterature that this zone represent a metabolic zone marked by apoptosis and inflammation rather than ischemia. We are planning to: When patients arrive in our stroke department they will within 7 hours be subject to MRI scan with the protocoled sequences. Standard sequences: Axial T2, axial DWI, Sagittal T1, T2 flair og axial GRE-sequence. Susceptibility weighted imaging (SWI) Chemical Shift Imaging (CSI) multivoxel spectroscopi Post contrast 3D box reconstruction After 8 weeks the patients are subject to another MRI-Scan in accordance with the standard clinical guideline to rule out underlying pathology. After 3 month the patients are seen in the outpatient-clinic to follow-up evaluation. To sum up the purpose of this present study is to conduct a pilot investigation of MRI in the early evaluation of ICH-patients. Second it is our intension to use multivoxel magnetic resonance spectroscopy to study the metabolic penumbra-zone surrounding the ICH. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02810899 -
Dexmedetomidine and Intelligence Development in Pediatric Patients Undergoing Craniotomy
|
Phase 4 | |
Withdrawn |
NCT00977795 -
A Study of the Specificity and Sensitivity of 5-ALA Fluorescence in Malignant Brain Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT00787982 -
Magnetic Resonance Imaging-Guided Laser Induced Thermal Therapy for Treatment of Metastatic Brain Tumors
|
Phase 1/Phase 2 | |
Withdrawn |
NCT00555984 -
Intravenous Anesthesia Versus Anesthesia With Volatile Agents in Elective Craniotomy for Tumors
|
N/A | |
Completed |
NCT00038441 -
Phase I Trial of Intramural Injection of DTI-015 for Recurrent Malignant Gliomas
|
Phase 1/Phase 2 | |
Recruiting |
NCT03619694 -
Role of MR Spectroscopy in Brain Tumors
|
||
Withdrawn |
NCT01236586 -
RO4929097 in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia
|
Phase 1 | |
Unknown status |
NCT02775136 -
An Evaluation of a Non-invasive Brain Monitor
|
N/A | |
Completed |
NCT01244737 -
FLT-PET Imaging of Brain Tumors in Children
|
Phase 2 | |
Completed |
NCT00993057 -
Efficiency of Two Glucose Sampling Protocols for Maintenance of Euglycemia
|
Early Phase 1 | |
Terminated |
NCT00769093 -
Assessing Dynamic Magnetic Resonance (MR) Imaging in Patients With Recurrent High Grade Glioma Receiving Chemotherapy
|
Phase 1 | |
Completed |
NCT00392119 -
MR Guided Laser Interstitial Thermal Therapy for the "Minimal Invasive" Treatment of Brain Metastasis and Primary Brain Tumors
|
Phase 1 | |
Terminated |
NCT00038389 -
Study of Vioxx and Radiation Therapy for Brainstem Glioma
|
Phase 1 | |
Completed |
NCT00062478 -
Study of Karenitecin (BNP1350) in Patients With Brain Tumors
|
Phase 2 | |
Recruiting |
NCT05049148 -
Platelets Activation in Brain Neoplasms
|
N/A | |
Terminated |
NCT02900248 -
CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice
|
||
Recruiting |
NCT04712721 -
Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress αvβ3 and αvβ5 Integrins.
|
Early Phase 1 | |
Completed |
NCT02881957 -
Hypovitaminosis D in Neurocritical Patients
|
Phase 2/Phase 3 | |
Terminated |
NCT01954576 -
NovoTTF Therapy in Treating Patients With Recurrent Glioblastoma Multiforme
|
N/A | |
Recruiting |
NCT05538130 -
A Study to Learn About the Study Medicine Called PF-07799544 in People With Advanced Solid Tumors
|
Phase 1 |